Evidence map›Paper›PMID 33456620›Full record

ArticleCognitive computation2021

Principal Component Analysis Applications in COVID-19 Genome Sequence Studies.

Bo Wang, Lin Jiang

Open access · bronzeAbstract read
In one paragraph

Article in Cognitive computation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Bo WangDepartment of Chemistry, College of Science and Technology, North Carolina Agricultural and Technical State University, Greensboro, NC 27411 USA.
Lin JiangDivision of Natural Sciences, New College of Florida, 5800 Bay Shore Road, Sarasota, FL 34243 USA.
New College of Florida · USNorth Carolina Agricultural and Technical State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA genomes from coronavirus have a length as long as 32 kilobases, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused the outbreak of coronavirus disease 2019 (COVID-19) pandemic has long sequences which made the analysis difficult. Over 20,000 sequences have been submitted to GISAID, and the number is growing fast each day which increased the difficulties in data analysis; however, genome sequence analysis is critical in understanding the COVID-19 and preventing the spread of the disease. In this study, a principal component analysis (PCA) was applied to the aligned large size genome sequences and the numerical numbers were converted from the letters using a published method designed for protein sequence cluster analysis. The study initialized with a shortlist sequence testing, and the PCA score plot showed high tolerance with low-quality data, and the major virus sequences from humans were separated from the pangolin and bat samples. Our study also successfully built a model for a large number of sequences with more than 20,000 sequences which indicate the potential mutation directions for the COVID-19 which can be served as a pretreatment method for detailed studies such as decision tree-based methods. In summary, our study provided a fast tool to analyze the high-volume genome sequences such as the COVID-19 and successfully applied to more than 20,000 sequences which may provide mutation direction information for COVID-19 studies.

Indexed as

COVID-19Genome SequencesMutationPrinciple Component Analysis

Identifiers

PMID33456620
PMCPMC7804214
OpenAlexW3120830985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.